-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Chemours, Raises Price Target to $30

Benzinga·05/08/2026 22:10:08
Listen to the news
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $29 to $30.